The Masonic Cancer Center (MCC) has successful recruited a strong and stable leadership team: ? Douglas Yee, MD, Director since 2007 ? Jeffrey Miller, MD, Deputy Director since 2012 ? Mary Sumpmann, MS, RN, founding Associate Director for Administration since 1991 ? Dorothy Hatsukami, PhD, Associate Director for Cancer Prevention and Control since 2008 ? David Largaespada, PhD, Associate Director for Basic Sciences since 2010 ? Selwyn Vickers, MD, Associate Director for Translational Research since 2008 ? Badrinath Konety, MD, Associate Director for Clinical Affairs since 2011 The following priorities were established by the leadership: ? Expand the scope of and resources for translational research via pilot finding, development of informatics resources, faculty recruitment, and mentoring of junior faculty ? Expand research capabilities by expanding research space and recruiting new laboratory-based investigators for a new MCC research building ? Create a new cancer outcomes and survivorship research focus or Program via recruitment, pilot funding, and training ? Re-examine the scope of the basic science programs ? ^ Integrate the Oncology Service Line into MCC operations and leadership, leveraging the research programs, clinical expertise, and resources ? Expand MCC support for health disparities efforts and integrate the efforts with MCC outreach through pilot funding, community engagement, resource development, peer-reviewed funding, and training MCC's senior leadership is highly engaged in the scientific, training, and catchment area strategies of the cancer center. The senior leadership meets monthly as part ofthe executive committee to review MCC operations, discuss objectives, and review the membership. Additionally, leadership retreats were held in August of 2008, 2011, and 2012.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Sarver, Aaron L; Murray, Collin D; Temiz, Nuri A et al. (2016) MYC and PVT1 synergize to regulate RSPO1 levels in breast cancer. Cell Cycle 15:881-5
Diep, Caroline H; Knutson, Todd P; Lange, Carol A (2016) Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming. Mol Cancer Res 14:141-62
Yun, Young Sung; Kim, Kwan Hyun; Tschida, Barbara et al. (2016) mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress. Mol Cell 61:625-39
Yan, Y; Hanse, E A; Stedman, K et al. (2016) Transcription factor C/EBP-β induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells. Cell Death Differ 23:1232-42
Beura, Lalit K; Hamilton, Sara E; Bi, Kevin et al. (2016) Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532:512-6
Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87
Struntz, Nicholas B; Harki, Daniel A (2016) Catch and Release DNA Decoys: Capture and Photochemical Dissociation of NF-κB Transcription Factors. ACS Chem Biol 11:1631-8
Knorr, David A; Wang, Hongbo; Aurora, Mukta et al. (2016) Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 22:825-33
Glasgow, Michelle; Vogel, Rachel Isaksson; Burgart, Jennifer et al. (2016) Long term follow-up of a phase II trial of multimodal therapy given in a ""sandwich"" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol Res Pract 3:6
Felices, Martin; Lenvik, Todd R; Davis, Zachary B et al. (2016) Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells. Methods Mol Biol 1441:333-46

Showing the most recent 10 out of 763 publications